Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer

Tryptophan 2,3‐dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma

(2021) Makoto Sumitomo et al.   CANCER SCIENCE

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

(2021) Corinne Faivre-Finn et al.   Journal of Thoracic Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

(2021) Luis Paz-Ares et al.   LANCET ONCOLOGY

Induction of Pyroptosis: A Promising Strategy for Cancer Treatment

(2021) Lei Wang et al.   Frontiers in Oncology

Next generation of immune checkpoint inhibitors and beyond

(2021) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Strategies to overcome resistance to immune checkpoint blockade in lung cancer

(2021) Ilaria Attili et al.   LUNG CANCER

Bispecific Antibodies: From Research to Clinical Application

(2021) Jiabing Ma et al.   Frontiers in Immunology

Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy

(2021) Simon Eschweiler et al.   NATURE IMMUNOLOGY

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises

(2020) Kleita Michaelidou et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Determinants of Resistance to Checkpoint Inhibitors

(2020) Linda Tran et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Necroptosis in Immuno-Oncology and Cancer Immunotherapy

(2020) Jenny Sprooten et al.   Cells

Mechanisms of Cancer Resistance to Immunotherapy

(2020) Rilan Bai et al.   Frontiers in Oncology

The Resistance Mechanisms of Lung Cancer Immunotherapy

(2020) Fen Wang et al.   Frontiers in Oncology

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

(2020) Laura Boyero et al.   Cancers

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

(2020) Marcin Nicoś et al.   Frontiers in Oncology

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

(2019) Lin Yu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

(2019) M D Hellmann et al.   ANNALS OF ONCOLOGY

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

(2019) C Luchini et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?

(2019) Yoshihiro Ohue et al.   CANCER SCIENCE

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

(2019) Urania Dafni et al.   LUNG CANCER

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges

(2019) Orgilmaa Regzedmaa et al.   OncoTargets and Therapy

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

(2019) Suzanne L. Topalian et al.   JAMA Oncology

Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response

(2019) Christopher A. Hamm et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer

(2019) Hongge Liang et al.   Cancer Management and Research

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

(2018) Robert D. Leone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

(2018) Elizabeth Dudnik et al.   Journal of Thoracic Oncology

Determinants and clinical implications of chromosomal instability in cancer

(2018) Laurent Sansregret et al.   Nature Reviews Clinical Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

(2017) Samra Turajlic et al.   LANCET ONCOLOGY

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies

(2017) Géraldine Genard et al.   Frontiers in Immunology

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Acquired and intrinsic resistance in cancer immunotherapy

(2014) Sander Kelderman et al.   Molecular Oncology

The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy

(2014) H.-J. Kim et al.   Cancer Immunology Research

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Cancer-Related Inflammation

(2012) Juliana Candido et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE